Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$17.79 - $30.86 $377,948 - $655,620
-21,245 Reduced 64.06%
11,920 $220,000
Q4 2023

Feb 13, 2024

BUY
$20.78 - $31.77 $31,918 - $48,798
1,536 Added 4.86%
33,165 $1.04 Million
Q3 2023

Nov 13, 2023

BUY
$20.84 - $33.47 $57,789 - $92,812
2,773 Added 9.61%
31,629 $659,000
Q2 2023

Aug 11, 2023

SELL
$17.8 - $25.65 $49,128 - $70,794
-2,760 Reduced 8.73%
28,856 $691,000
Q1 2023

May 12, 2023

BUY
$16.32 - $20.92 $233,767 - $299,658
14,324 Added 82.84%
31,616 $595,000
Q4 2022

Feb 13, 2023

SELL
$14.2 - $18.63 $182,129 - $238,948
-12,826 Reduced 42.59%
17,292 $275,000
Q3 2022

Nov 14, 2022

BUY
$14.11 - $18.27 $227,608 - $294,713
16,131 Added 115.33%
30,118 $493,000
Q2 2022

Aug 12, 2022

SELL
$13.01 - $27.22 $123,087 - $257,528
-9,461 Reduced 40.35%
13,987 $197,000
Q1 2022

May 13, 2022

BUY
$20.94 - $27.5 $294,395 - $386,622
14,059 Added 149.74%
23,448 $568,000
Q4 2021

Feb 11, 2022

BUY
$16.79 - $27.09 $157,641 - $254,348
9,389 New
9,389 $219,000
Q1 2021

May 14, 2021

SELL
$25.02 - $54.99 $178,968 - $393,343
-7,153 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$41.04 - $56.79 $347,321 - $480,613
-8,463 Reduced 54.19%
7,153 $382,000
Q3 2020

Nov 13, 2020

BUY
$36.42 - $57.0 $406,847 - $636,747
11,171 Added 251.32%
15,616 $644,000
Q2 2020

Aug 10, 2020

BUY
$39.26 - $52.73 $174,510 - $234,384
4,445 New
4,445 $215,000
Q1 2019

May 02, 2019

SELL
$16.17 - $27.38 $11,610 - $19,658
-718 Closed
0 $0
Q4 2018

Feb 08, 2019

BUY
$14.32 - $22.92 $10,281 - $16,456
718 New
718 $12,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.65B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Pearl River Capital, LLC Portfolio

Follow Pearl River Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pearl River Capital, LLC with notifications on news.